Biocon Targets Q1 2027 Launch of Pertuzumab Biosimilar After Genentech Deal

Biocon reached a global patent settlement and licensing agreement with Genentech, resolving disputes over its pertuzumab biosimilar Pebrilzo. The company is targeting launches in the first quarter of 2027.